United States-based VBI Vaccines has collaborated with United Kingdom-based GlaxoSmithKline to clinically assess the combination of VBI-1901, VBI's cancer vaccine immunotherapeutic, with GSK's proprietary AS01B adjuvant system, it was reported yesterday.
Under the partnership, VBI Vaccines is planning to add an additional study arm to Part B of the company's ongoing Phase 1/2a clinical study targeting recurrent glioblastoma, a cytomegalovirus-associated tumour.
In Part A of the study, the product adjuvanted with granulocyte-macrophage colony-stimulating factor was well-tolerated at all doses, while three out of six patients in a high-dose (10 µg) cohort showcased evidence of stable disease by magnetic resonance imaging that correlated with vaccine-induced immune response. The high-dose has been identified as the optimal therapeutic dose to test in the Part B extension phase of the study. Part B of the ongoing Phase 1/2a clinical study is now planned to be a two-arm, open-label study, enrolling 20 first-recurrent GBM patients to receive VBI-1901 in combination with either GM-CSF or AS01B as immunomodulatory adjuvants.
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study
Precision Epigenomics partners with TruDiagnostic
Modalis partners with Ginkgo Bioworks
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Algiax Pharmaceuticals reveals update on chronic neuropathic pain study